Anticancer agents against malaria: time to revisit?

Trends in Parasitology

Volumn 26, Issue 3, 2010, Pages 125-129

  Nzila, Alexis ^a,b   Okombo, John ^a   Becker, Ruy Perez ^c   Chilengi, Roma ^a,b   Lang, Trudie ^a,b   Niehues, Tim ^c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMINOPTERIN; ANTINEOPLASTIC AGENT; ARTEMISININ; AZITHROMYCIN; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CYCLOPHOSPHAMIDE; DAPSONE; DOCETAXEL; DOXYCYCLINE; EDATREXATE; EFLORNITHINE; ERYTHROMYCIN; FOLIC ACID DERIVATIVE; FOLINIC ACID; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MILTEFOSINE; PACLITAXEL; PIRITREXIM; PRALATREXATE; PYRIMETHAMINE; QUININE; THALIDOMIDE; TRIMETREXATE; TUBULOZOLE; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADD ON THERAPY; AFRICAN TRYPANOSOMIASIS; ALOPECIA; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; BURKITT LYMPHOMA; CHRONIC MYELOID LEUKEMIA; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; EYE DISEASE; FATIGUE; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GRAFT REJECTION; HEAD AND NECK CANCER; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMORRHAGIC CYSTITIS; HIRSUTISM; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; INFERTILITY; JUVENILE RHEUMATOID ARTHRITIS; KAPOSI SARCOMA; KIDNEY CANCER; LEISHMANIASIS; LEPROSY; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALARIA; MALARIA FALCIPARUM; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MYELODYSPLASTIC SYNDROME; NAUSEA; NEOPLASM; NEPHROBLASTOMA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OTOTOXICITY; OVARY CANCER; PLASMODIUM FALCIPARUM; PNEUMOCYSTIS PNEUMONIA; PRIMARY BILIARY CIRRHOSIS; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RETINOBLASTOMA; RHABDOMYOSARCOMA; RHEUMATOID ARTHRITIS; SCHISTOSOMIASIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TROPHOBLASTIC TUMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WEGENER GRANULOMATOSIS;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; HUMANS; MALARIA; METHOTREXATE; TRIMETREXATE;

EID: 76749134217     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2009.12.002     Document Type: Article

References (57)

1. Nosten F., and White N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77 (2007) 181-192
2. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361 (2009) 455-467
3. Miller T.M., and Layzer R.B. Muscle cramps. Muscle Nerve 32 (2005) 431-442
4. Sibilia J., and Pasquali J.L. Systemic lupus erythematosus: news and therapeutic perspectives. Presse Med. 37 (2008) 444-459
5. Efferth T. Willmar Schwabe Award 2006: Antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med. 73 (2007) 299-309
6. Utzinger J., et al. Artemisinins for schistosomiasis and beyond. Curr. Opin. Investig. Drugs 8 (2007) 105-116
7. Chico R.M., et al. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar. J. 7 (2008) 255
8. Croft, A.M. (2005) Malaria: prevention in travellers. Clin. Evid. 954-972
9. Wolf R., et al. Dapsone. Dermatol. Online J 8 (2002) 2
10. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemother. 57 (2006) 1043-1054
11. Kiara S.M., et al. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. Antimicrob. Agents Chemother. 53 (2009) 3793-3798
12. Pytel D., et al. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med. Chem. 9 (2009) 66-76
13. Langman L.J., and Kapur B.M. Toxicology: then and now. Clin. Biochem. 39 (2006) 498-510
14. Rozman K.K., and Doull J. Paracelsus, Haber and Arndt. Toxicology 160 (2001) 191-196
15. Taylor W.R., and White N.J. Antimalarial drug toxicity: a review. Drug Safety 27 (2004) 25-61
16. Cann H.M., and Verhulst H.L. Fatal acute chloroquine poisoning in children. Pediatrics 27 (1961) 95-102
17. Riou B., et al. Treatment of severe chloroquine poisoning. N. Engl. J. Med. 318 (1988) 1-6
18. Chabner B.A., et al. Antineoplastic agents. In: Brunton L. (Ed). The Pharmacological Basis of Therapeutics. 9th edn (2006), McGraw-Hill 1315-1465
19. Niehues T., and Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr. Drugs 8 (2006) 347-356
20. Swierkot J., and Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol. Rep. 58 (2006) 473-492
21. Gray O.M., et al. A systematic review of oral methotrexate for multiple sclerosis. Multiple Sclerosis 12 (2006) 507-510
22. Domenech E., et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J. Clin. Gastroenterol. 42 (2008) 395-399
23. Montero Mora P., et al. Autoimmune urticaria. Treatment with methotrexate. Rev. Alerg. Mex. 51 (2004) 167-172
24. Chen J. Is methotrexate effective for the treatment of ankylosing spondylitis?. Nat. Clin. Practice 3 (2007) 490-491
25. Bosman T., et al. Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature. Rheumatol. Int. 28 (2008) 713-718
26. Novak K., and Swain M.G. Role of methotrexate in the treatment of chronic cholestatic disorders. Clin. Liver Dis. 12 (2008) 81-96 viii
27. Specks U. Methotrexate for Wegener's granulomatosis: what is the evidence?. Arthritis Rheum. 52 (2005) 2237-2242
28. Gong Y., and Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst. Rev. (2005) CD004385
29. Wong J.M., and Esdaile J.M. Methotrexate in systemic lupus erythematosus. Lupus 14 (2005) 101-105
30. Stawell R. Methotrexate in inflammatory eye disease. Ocul. Immunol. Inflamm. 11 (2003) 79-82
31. Henter J.I., et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48 (2007) 124-131
32. Tahiri L., et al. Therapeutic maintenance level of methotrexate in rheumatoid arthritis. Sante 16 (2006) 167-172
33. Sheehy T.W., and Dempsey H. Methotrexate therapy for Plasmodium vivax malaria. J. Am. Med. Assoc. 214 (1970) 109-114
34. Wildbolz A. Methotrexate in the therapy of malaria. Ther. Umsch. 30 (1973) 218-222
35. Ferone R. Methotrexate therapy for P. vivax malaria. J. Am. Med. Assoc. 215 (1971) 117
36. Laing A.B. Methotrexate in malaria. Trans. R. Soc. Trop. Med. Hyg. 66 (1972) 518-519
37. Chladek J., et al. Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin. Pharmacol. Toxicol. 96 (2005) 247-248
38. Chladek J., et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br. J. Clin. Pharmacol. 54 (2002) 147-156
39. Haller D.G. Trimetrexate: experience with solid tumors. Semin. Oncol. 24 (1997) S18-71-S18-76
40. Nduati E., et al. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol. Res. 102 (2008) 1227-1234
41. Walzer P.D., et al. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36 (1992) 1935-1942
42. Fulton B., et al. Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs 49 (1995) 563-576
43. Marshall J.L., and DeLap R.J. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin. Pharmacokinet. 26 (1994) 190-200
44. Fennell B.J., et al. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J. Antimicrob. Chemother. 51 (2003) 833-841
45. Koka S., et al. Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol. Biochem. 23 (2009) 191-198
46. Schrevel J., et al. Interactions between docetaxel (Taxotere) and Plasmodium falciparum-infected erythrocytes. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8472-8476
47. Sinou V., et al. In vitro and in vivo inhibition of erythrocytic development of malarial parasites by docetaxel. Antimicrob. Agents Chemother. 40 (1996) 358-361
48. Usanga E.A., et al. Mitotic inhibitors arrest the growth of Plasmodium falciparum. FEBS Lett. 209 (1986) 23-27
49. Nair L., and Bhasin V.K. Cure with cisplatin (II) or murine malaria infection and in vitro inhibition of a chloroquine-resistant Plasmodium falciparum isolate. Jpn. J. Med. Sci. Biol. 47 (1994) 241-252
50. Kreidenweiss A., et al. Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar. J. 7 (2008) 187
51. Nannini C., et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res. Ther. 10 (2008) R124
52. Prefontaine E., et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. (2009) CD000067
53. Wu J.J., et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol. 153 (2005) 254-273
54. Mateos J., et al. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant. 37 (2006) 337-338
55. Balasegaram M., et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans. R. Soc. Trop. Med. Hyg. 103 (2009) 280-290
56. Hickman J.G., et al. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr. Med. Res. Opin. 16 (2001) 235-244
57. Berman J.J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin. Drug Metab. Toxicol. 4 (2008) 1209-1216